RxDoctor Payments DataLook up a doctor →

Hind Obid, MD

Allergy & Immunology · Panama City, FLNPI 1043298151

Payments from drug & device makers

$22,682in general payments, 2019–2025

Across 954 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$3K
  • Grifols USA, LLC$2K
  • Boehringer Ingelheim$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • plus $10K from 50 others

What the payments were for

  • Consulting fees$240%
  • Food & beverage$22,37199%
  • Education$2881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,682 in reported general payments places this provider in the 75th percentile of 204 allergy & immunology providers in Florida.

See all allergy & immunology providers in Florida

Medicare billing

Part B allowed, 2024
$486,958
Medicare patients
371
Services billed
31,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$41,272
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$20,740
XolairOmalizumab13$18,004
Breo ElliptaFluticasone/Vilanterol12$12,463
Ipratropium Bromide72$3,699
Albuterol Sulfate HfaAlbuterol Sulfate62$1,965
Fluconazole58$1,603
Fluticasone Propionate74$1,470
Azelastine Hcl19$1,051
Montelukast Sodium77$982
Levocetirizine Dihydrochloride29$647
Omeprazole29$583
Famotidine32$551
Hydroxyzine Hcl16$551
Cefdinir24$427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,591$53,73447 claims
AstraZenecaBreztri Aerosphere$4,195$20,74015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 204 allergy & immunology providers in Florida.

Other allergy & immunology in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →